# COCOON (NCT06120140)

> Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06120140
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Amivantamab IV; Amivantamab SC; Lazertinib; Doxycycline; Minocycline; Clindamycin; Chlorhexidine; Noncomedogenic skin moisturizer; Ruxolitinib; Tacrolimus; Zinc gluconate; Propranolol; Timolol; Clobetasol
- Enrollment: 305
- Primary outcome: Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cocoon-nct06120140